Company intelligence / Profile preview

Therakos

Raritan, New Jersey, United Statestherakos.com ↗

Ownership: Private
Development stage: Other

Overview

Therakos leads the global market in extracorporeal photopheresis systems for autologous immunomodulatory therapy. Its CELLEX platform has delivered over one million treatments worldwide and holds regulatory approvals across major markets. The company’s technology provides a unique therapeutic option for patients with complex immune-related diseases such as GVHD and CTCL. Clinical results have established its safety profile and efficacy as an adjunct or alternative when other therapies fail.[1][3]

Therapeutic areas: ImmunologyOncology
Modalities: Device (Extracorporeal Photopheresis system)Cell therapy (Autologous immune cell therapy)Biologic (as part of the immunomodulatory process)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Therakos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Therakos.

Explore the full profile